ArticleCancer management and research2018
LncRNAs and
Article in Cancer management and research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 2 syntheses or guidelines pooled it, 48 citations in OpenAlex.
- Tumor Educated Platelets as a Biomarker for Diagnosis of Lung cancer: A Systematic Review.Asian Pacific journal of cancer prevention : APJCP · 2024Pooled it
- Clinical utility and diagnostic value of tumor-educated platelets in lung cancer: a systematic review and meta-analysis.Frontiers in oncology · 2023Pooled it
- Towards liquid biopsy-based analysis of antitumour immunity.Nature reviews. Clinical oncology · 2026Review
- Non-coding RNAs in tumor-educated platelets: emerging roles in cancer progression, biomarker discovery, and therapeutic targeting.Frontiers in oncology · 2026Review
- The role of platelets in cancer: from their influence on tumor progression to their potential use in liquid biopsy.Biomarker research · 2025Review
- Analysis and exploration of regulatory mechanisms and potential prognostic biomarkers in squamous cell carcinoma of the lung by expression profiling.Translational cancer research · 2025Article
- Tumor-Educated Platelets lncRNA-STARD4-AS1 and ELOA-AS1 as Potential Novel Biomarkers for the Early Diagnosis of Non-Small Cell Lung Cancer.Cancer management and research · 2025Article
- Long-Term Outcomes in Patients with EGFR Positive Lung Adenocarcinoma and Subgroup Analysis Based on Presence of Liver Metastases.Current issues in molecular biology · 2024Article
- Roles of Tumor-Educated Platelets (TEPs) in the biology of Non-Small Cell Lung Cancer (NSCLC): A systematic review. "Re-discovering the neglected biosources of the liquid biopsy family".The journal of liquid biopsy · 2024Review
- TEP RNA: a new frontier for early diagnosis of NSCLC.Journal of cancer research and clinical oncology · 2024Review
- Prospects of liquid biopsy in the prognosis and clinical management of gastrointestinal cancers.Frontiers in molecular biosciences · 2024Review
- Liquid biopsy: creating opportunities in brain space.British journal of cancer · 2023Review
- Tumor-educated platelet blood tests for Non-Small Cell Lung Cancer detection and management.Scientific reports · 2023Article
- Tumor educated platelet: the novel BioSource for cancer detection.Cancer cell international · 2023Review
- Contents in tumor-educated platelets as the novel biosource for cancer diagnostics.Frontiers in oncology · 2023Review
- Liquid biopsy: an examination of platelet RNA obtained from head and neck squamous cell carcinoma patients for predictive molecular tumor markers.Exploration of targeted anti-tumor therapy · 2023Article
- LncRNAs in non-small cell lung cancer: novel diagnostic and prognostic biomarkers.Frontiers in molecular biosciences · 2023Review
- Liquid biopsy at the frontier of detection, prognosis and progression monitoring in colorectal cancer.Molecular cancer · 2022Review
- Methods for the Detection of Circulating Biomarkers in Cancer Patients.Advances in experimental medicine and biology · 2022Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTissue biopsy-based cancer diagnosis has limitations because of the fact that tumor tissues are in constant evolution and extremely heterogeneous. The current study was aimed to examine whether tumor-educated blood platelets (TEPs) might be a potential all-in-one source for blood-based cancer diagnostics to overcome the limitations of conventional cancer biopsy.
methodsIn the present study, we evaluated the expression pattern of MAGI2 antisense RNA 3 (
resultsOur results showed that the levels of
conclusionOur data suggested that TEP is a promising source for NSCLC diagnosis and companion diagnostics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.